![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Department of Pediatrics, Division of Digestive, Endocrine, Genetic, and Nutritional Disorders, University of Arkansas for Medical Science, Arkansas Children's Hospital, Little Rock, AR 72202-3591
In studies using an avidin-binding assay to measure the serum or plasma concentration of biotin, biotin is sometimes assumed to be equal to the avidinbinding substances detected. To provide a range of values for serum concentrations of biotin, bisnorbiotin, and biotin sulfoxide, HPLC was used to separate avidinbinding substances in human serum, and the chromatographic fractions were assayed for avidin-binding substances (biotin and biotin metabolites). In sera from 15 normal fasting adults, substantial concentrations of avidin-binding substances other than biotin were detected. Two of the principal substances were identified as bisnorbiotin and biotin sulfoxide based on their chromatographic properties. The serum concentrations of bisnorbiotin and biotin sulfoxide varied widely among the individuals. In three subjects, the concentration of bisnorbiotin exceeded that of biotin. The presence of avidinbinding substances in addition to biotin may have confounded previous measurements of the concentration of biotin in serum, plasma, and blood when avidin-binding assays were used. Because bioassay methods for biotin sometimes use organisms for which one or more of these biotin metabolites are growth factors, measurements of biotin in blood using some bioassays are likely to overestimate the concentrations of biotin.
KEY WORDS: • biotin • humans • blood • biotin metabolite
1 Supported by grants from the National Institutes of Health to D.M.M. (DK36823).
2 The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.
3 To whom correspondence should be addressed.
Manuscript received 8 June 1994. Revision accepted 11 October 1994.
This article has been cited by other articles:
|
|
 |
|
  T. Kuroishi, Y. Endo, K. Muramoto, and S. Sugawara Biotin deficiency up-regulates TNF-{alpha} production in murine macrophages J. Leukoc. Biol., April 1, 2008; 83(4): 912 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Daniels, P. P. Ng, T. Delgado, M. R. Lynch, G. Schiller, G. Helguera, and M. L. Penichet Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells Mol. Cancer Ther., November 1, 2007; 6(11): 2995 - 3008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ferreira, W. P. Weiss, and L. B. Willett Changes in Measures of Biotin Status Do Not Reflect Milk Yield Responses When Dairy Cows Are Fed Supplemental Biotin J Dairy Sci, March 1, 2007; 90(3): 1452 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rodriguez-Melendez, J. B. Griffin, and J. Zempleni Biotin Supplementation Increases Expression of the Cytochrome P450 1B1 Gene in Jurkat Cells, Increasing the Occurrence of Single-Stranded DNA Breaks J. Nutr., September 1, 2004; 134(9): 2222 - 2228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rodriguez-Melendez, G. Camporeale, J. B. Griffin, and J. Zempleni Interleukin-2 receptor-gamma -dependent endocytosis depends on biotin in Jurkat cells Am J Physiol Cell Physiol, February 1, 2003; 284(2): C415 - C421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M Mock, C. L Henrich, N. Carnell, and N. I Mock Indicators of marginal biotin deficiency and repletion in humans: validation of 3-hydroxyisovaleric acid excretion and a leucine challenge Am. J. Clinical Nutrition, November 1, 2002; 76(5): 1061 - 1068. [Abstract] [Full Text] [PDF]
|
|
